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Abstract
Introduction: The seroprevalence of human T-cell leukemia virus type 1 (HTLV-1) is very high among Brazilians (,1:200).
HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP) is the most common neurological complication of
HTLV-1 infection. HAM/TSP can present with an acute/subacute form of longitudinally extensive myelitis, which can be
confused with lesions seen in aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorders (NMOSD)
on MRI. Moreover, clinical attacks in patients with NMOSD have been shown to be preceded by viral infections in around
30% of cases.
Objective: To evaluate the frequency of AQP4-Ab in patients with HAM/TSP. To evaluate the frequency of HTLV-1 infection
in patients with NMOSD.
Patients and Methods: 23 Brazilian patients with HAM/TSP, 20 asymptomatic HTLV-1+ serostatus patients, and 34 with
NMOSD were tested for AQP4-Ab using a standardized recombinant cell based assay. In addition, all patients were tested for
HTLV-1 by ELISA and Western blotting.
Results: 20/34 NMOSD patients were positive for AQP4-Ab but none of the HAM/TSP patients and none of the
asymptomatic HTLV-1 infected individuals. Conversely, all AQP4-Ab-positive NMOSD patients were negative for HTLV-1
antibodies. One patient with HAM/TSP developed optic neuritis in addition to subacute LETM; this patient was AQP4-Ab
negative as well. Patients were found to be predominantly female and of African descent both in the NMOSD and in the
HAM/TSP group; Osame scale and expanded disability status scale scores did not differ significantly between the two
groups.
Conclusions: Our results argue both against a role of antibodies to AQP4 in the pathogenesis of HAM/TSP and against an
association between HTLV-1 infection and the development of AQP4-Ab. Moreover, the absence of HTLV-1 in all patients
with NMOSD suggests that HTLV-1 is not a common trigger of acute attacks in patients with AQP4-Ab positive NMOSD in
populations with high HTLV-1 seroprevalence.
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Introduction
Neuromyelitis optica (NMO) is an inflammatory disease of the
central nervous system (CNS) of putative autoimmune aetiology,
which is characterized by severe attacks of myelitis and optic
neuritis (ON) [1,2]. In 60–80% of cases, NMO is associated with
antibodies to aquaporin-4 (AQP4-Ab), the most abundant water
channel in the CNS [3–4]. AQP4-Ab are also detectable in around
60% of patients with isolated longitudinally extensive transverse
myelitis (LETM) [5] and in 5–25% of patients with recurrent,
isolated ON [6–8], which are therefore considered formes frustes of
NMO. NMO, LETM, and ON are often referred to as ‘NMO
spectrum disorders’ (NMOSD) [9].
It is estimated that 15 to 20 million individuals are infected with
the human T-cell leukemia virus type 1 (HTLV-1) worldwide [10].
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HTLV-1 infection remains asymptomatic in the vast majority of
cases, yet less than 5% of affected individuals will develop two
major diseases: adult T-cell leukaemia/lymphoma (ATL) and
HTLV-1 associated myelopathy or tropical spastic paraparesis
(HAM/TSP) [11]. While HAM/TSP’s pathogenesis is not fully
understood, it is thought to be related to a high HTLV-1 provirus
burden and an exaggerated proinflammatory cellular immune
response, leading to a chronic extensive myelitis [12]. Some case
reports have described an acute variant of HAM/TSP, charac-
terized by longitudinally extensive transverse myelitis (LETM) on
magnetic resonance imaging (MRI), a key feature of neuromyelitis
optica (NMO), which may or may not be associated with ON [13–
16].
There are few population-based epidemiological studies of
NMOSD, but it seems that the disease is more prevalent in peoples
of Asian, African-American or Hispanic background when
compared with those of Northern European descent [17–19].
Accordingly, the proportion of NMOSD patients among all
patients with CNS demyelinating disorders is high in Brazil [20].
At the same time, Brazil is among the countries with the highest
prevalence of HTLV-1 infected individuals [12,21]. Moreover,
both among patients with AQP4-Ab positive NMOSD and among
patients with HAM/TSP an afrodescendant predilection was
reported [12,22–24].
As testing for aquaporin-4 antibodies (AQP4-Ab) became
available only few years ago, cases of AQP4-Ab positive LETM
occurring in the context of HTLV-1 seropositivity might thus have
been misdiagnosed as acute HAM/TSP in a subset of patients in
the past. Furthermore, AQP4-Ab positive NMO was shown to be
frequently preceded by viral or bacterial infections and HTLV-1
infection may act as a trigger of NMO in some cases [1–2].
This study aimed to determine the seroprevalence of antibodies
to AQP4 in patients with HTLV-1 associated myelopathy (HAM/
TSP) and that of HTLV-1 antibodies in patients with neuromy-
elitis optica spectrum disorders (NMOSD) and to compare the
clinical characteristics of a HAM/TSP and NMOSD in Brazilian
patients.
Patients and Methods
Patients
This is a cross-sectional study that included along with regular
visits NMOSD patients who were followed-up at the neurological
outpatient unit of the University of Campinas (UNICAMP)
Hospital as well as HTLV-1 seropositive asymptomatic and
HAM/TSP patients attending the outpatient clinic at the Emilio
Ribas State Reference Institute of Infectious Diseases and at the
UNICAMP Hospital, Sa˜o Paulo, Brazil, during the period of
January 2011 to January 2012.
At each appointment, demographic and clinical data were
collected and the neurological statuses were evaluated by different
scales, including the EDSS [25] and Osame scales [26]. We
excluded from the study other causes of transverse myelitis,
clinically and radiologically, such as spinal cord compression,
infectious myelopathy, including parasitic etiology (e.g. Schistosoma
mansoni, which is endemic in northeast Brazil) [27], spinal cord
ischemia or bleeding, vitamin B12 and folate deficiency, among
others. We also excluded patients co-infected with hepatitis C virus
(HCV), hepatitis B virus (HBV), human immunodeficiency virus
types 1 and 2 (HIV-1/2) and HTLV type 2 in the HTLV-1
seropositive group. We decided to exclude these potentially
confounding factors, because these viruses co-infection could
interact and transactivate each other, thus altering the clinical
presentation of the myelopathy. Moreover, HIV itself may cause
vacuolar myelopathy, which shares some neurological traits with
HAM/TSP and could turn it difficult to determine which virus
was causing the clinical myelopathy [28].
Peripheral blood samples were collected from patients diag-
nosed with HAM/TSP as defined by World Health Organization
(WHO) criteria [29], from asymptomatic individuals with positive
HTLV-1 serostatus, from patients diagnosed with NMO spectrum
disorders (NMOSD) [30], and from healthy controls (HC)
(Table 1). NMO was diagnosed according to Wingerchuk’s revised
2006 criteria without the need for positive AQP4-Ab testing.
LETM was defined as acute myelitis with spinal cord lesions
extending over three or more vertebral segments on magnetic
resonance imaging; the median time between onset of transverse
myelitis symptoms and spinal MRI in the LETM group was 7 days
(range, 5–25 days). ON was defined as the occurrence of at least
two episodes of clinical optic neuritis, with an interval of more
than 30 days between them, and of no brain lesions outside the
optic nerves.
Ethics Statement
UNICAMP and Emilio Ribas Institute of Infectious Diseases
Ethics Committees for Research approved the study and all
patients provided informed written consent. On the behalf of the
minors/children participants involved in our study, we obtained
informed written consent from one of their parents.
Methods
We tested all peripheral blood samples for AQP4-Ab in a
standardized cell based immunofluorescence assay (Figure 1)
employing recombinant human AQP4 (Euroimmun AG, Ger-
many) [31] at the Neuroimmunology Laboratory of the University
of Campinas and for HTLV-1 in a commercial enzyme
immunosorbent assay (ELISA) kit (HTLV-I/II ELISA 4.0, MP
Diagnostics, Germany). When a serum sample tested positive, it
was confirmed by a Western blot (WB) assay (HTLVblot 2.4, MP
Diagnostics, Germany) at the Laboratory of Retrovirology of
Emilio Ribas Institute of Infectious Diseases. Data were analyzed
using GraphPad Prism 5. Statistical significance of differences was
determined by Chi-square or Fisher’s exact test for binominal
outcomes and by ANOVAs without assuming Gaussian distribu-
tion (Kruskal-Wallis test) and subsequent Dunn’s multiple
comparison tests. Differences were considered statically significant
with p values ,0.05.
Results
Detection of AQP4-Ab in Serum of Patients with NMOSD,
HAM/TSP and Healthy Control
Serum AQP4-Ab were detected in 20 out of 34 (59%) patients
in the NMOSD group, which included patients with NMO
(positive in 14/17 cases) and patients with syndromes considered
to confer a high risk for conversion to NMO (recurrent ON or
LETM; positive in 6/17 cases) (see Table 1 for details), but in none
of the patients previously diagnosed with HAM/TSP (n = 23), in
none of the patients with positive HTLV-1 serostatus but no
neurological symptoms at the time of presentation (n = 20), and in
none of the HCs (n = 23) (p,0.0001; Chi-square test). Moreover,
while all patients previously diagnosed with HAM/TSP were
positive for HTLV-1 antibodies, as detected by ELISA and
confirmed by WB assay, all patients with NMOSD were negative.
During the study, we excluded two asymptomatic patients that
turned out to be infected with HTLV type 2 after WB test and
three HAM/TSP patients that were co-infected with HCV and/or
HIV1/2. All of them tested negative for serum AQP4-Ab.
AQP4-Ab Are Not Related to HTLV-1 Infection
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e39372
Clinical Characteristics and Comparison of the Study
Population
The demographic and baseline clinical characteristics of the
study population are shown in Table 1. Most patients of the
HAM/TSP group had progressive lower limb weakness and
muscle spasticity, sensory disturbances, dorsal pain, neurogenic
bladder, and bowel and sexual dysfunction. The patients with
NMOSD usually presented severe attacks of ON, with poor
recovery leading to low vision, with no or only light perception in
one or both eyes, and/or myelitis with severe motor disability and
deep sense and sphincters disturbance. Pain was also frequent,
occurring in 8 out of 11 (73%) in the LETM group and in 12 out
of 17 (71%) in the NMO group, and usually affected one or more
areas of the chest, waist, legs, and back.
One patient developed an atypical form of HAM/TSP with
relapsing subacute LETM and ON. HTLV-1 antibodies were
detectable in serum and in the cerebrospinal fluid (CSF) of this
patient by western blot analysis; by contrast, serum AQP4-Ab
were negative. Moreover, in vitro culture of T-cells from this
patient’s peripheral blood mononuclear cells (PBMC) revealed an
elevated spontaneous proliferative response when compared with a
healthy control. After cells were cultured for 48h and pulsed with
thymidine during 18h, the proliferative response were determi-
nated by the mean incorporation of thymidine in DNA, and
indicated as counts per minute (cpm). This spontaneous prolifer-
ation of PBMC in vitro is an immunopathologic characteristic of
HTLV-1–infected individuals, driven by the HTLV-1-encoded
TAX protein and indicate the exaggerated proinflammatory
cellular immune response [12,32].
In the NMOSD group, no difference regarding gender was
found between AQP4-Ab positive and negative patients (p = 0.23,
Fisher’s exact test). 15 out 32 (47%) patients self-reported their
ethic origin as afrodescendant in the NMOSD group, 9 out of 17
(53%) in the HAM/TSP group, and 7 out 15 (47%) in the HTLV-
1+ group.
Regarding the median degree of disability, as measured by
Osame scale (p = 0.47) and EDSS (p = 0.52), there were no
statistically significant differences between the three groups
(Figure 2). An Osame scale score .= 4 (unilateral walking aid
needed) was found in 80% of the HAM/TSP patients, in 47% of
the NMO patients, and in 54% of the LETM patients. An EDSS
score $6.5 (constant bilateral assistance needed to walk at least 20
meters without resting) had 60% of the HAM/TSP patients, 41%
of the NMO patients, and 45% of the LETM patients.
Discussion
Our findings are relevant not only from a diagnostic but also
from a pathophysiological point of view. HTLV-1 infection is
highly prevalent among Brazilians, and patients with HAM/TSP
can present with an acute/subacute form of longitudinally
extensive myelitis, which can be confused with LETM lesions
seen in NMOSD on MRI. Our results argue both against a role of
antibodies to AQP4 in the pathogenesis of HAM/TSP and against
an association between HTLV-1 infection and the development of
AQP4-Ab. Moreover, the fact that antibodies to HTLV-1 were
absent in all patients with NMOSD suggests that HTLV-1 is not a
common trigger of acute attacks in patients with AQP4-Ab
positive NMOSD, a disorder in which relapses are often preceded
by infection, in populations with high HTLV-1 seroprevalence.
NMOSDandHAM/TSParebothhighlyprevalent insomeglobal
areas. In Japan and in Martinique, for example, NMOSD accounts
for around 40% and 17.3% of cases of CNS demyelinating diseases,
respectively, and these areas also feature a high prevalence of HTLV-
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Figure 1. Cell based assay. Antibodies to aquaporin-4 (AQP4) as detected by binding of patient IgG to HEK293 cells transfected with human full
length AQP4 (left column) but not to non-transfected control HEK293 cells (right column). 1A and B: Positive AQP4-Ab test in a patient with NMO
according to Wingerchuk’s 2006 criteria [29]. 2A and B: Negative AQP4-Ab test in a patient with HAM/TSP as defined by World Health Organization
criteria [28].
doi:10.1371/journal.pone.0039372.g001
Figure 2. Disease duration and disability. (A and B) Disability scores as measured by the Osame scale (p = 0.52, Kruskal Wallis Test) and by the
EDSS scores (p = 0.35, Kruskal Wallis Test) did not differ significantly between patients with established NMO, non-HTLV-1-associated LETM, and HAM/
TSP. (C) The fact that the median Osame and EDSS scores did not differ between LETM and the other groups despite shorter disease duration in the
LETM group reflects the rapid accumulation of disability in NMOSD as described before (p,0.0001, Kruskal Wallis Test. Dunn’s multiple comparison
test did not demonstrate significant difference between NMO vs. HAM/TSP groups) [1,2].
doi:10.1371/journal.pone.0039372.g002
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1 infection [12,18,19]. In Brazil, around 30% of patients with CNS
demyelinating diseases present with optic spinal symptoms and
around 12% with strict NMO [20]. The seroprevalence of HTLV-1
has been reported to be 0.45% among volunteer blood-donors in
Brazil in a nationwide survey [21]. Epidemiological studies indicate
that NMOSD more commonly affects patients of non-Caucasian
background [17], as do HTLV-1 infection. Similarly, a higher
proportion of afrodescendants and Asians than Caucasians has been
foundamongBrazilianHTLV-1patients [22]; the latter facthasbeen
discussed to reflect the African origin of HTLV-1, which is thought to
be derived from primate T-lymphotropic virus (PTLV) and later
spreading with the old population’s migratory pathway [12].
Accordingly, we found a high proportion of individuals with
afrodescendant both in the NMOSD and in the HAM/TSP group
in our study.
Regarding the patients’ epidemiological data, we found an older
median age at onset in the HAM/TSP group compared to the
NMOSD group in accordance with the literature, possibly
reflecting the long latency of HTLV-1 infection [9,29]. A female
preponderance was found in all groups. While the higher
proportion of females in the HAM/TSP group can be explained
by the higher sexual transmission efficiency from men to women
than from women to men [33], that observed in the NMOSD
group is in line with the putative autoimmune aetiology of this
disorder; female preponderance is a common characteristic of
many autoimmune diseases [34].
The relative high EDSS and Osame scores in the NMOSD
group as compared to the HAM/TSP group despite a shorter
disease duration reflects the attack severity in NMOSD with
poor recovery [1,2], which is in contrast with the mostly
progressive course of disease in HAM/TSP. The frequency and
distribution of pain symptoms in the NMOSD group is in line
with the literature [2,35]. The relatively low frequency of CSF
oligoclonal bands (29%) in our NMOSD patients is also in
accordance with previous studies, which consistently demon-
strated a lower frequency of CSF OCB when compared to
multiple sclerosis patients [1,36,37].
In conclusion, our findings indicate that misdiagnosis of
NMOSD as HAM/TSP is rare and support the view that LETM
associated to either HAM/TSP or NMO are distinct disorders,
which are likely to be pathogenetically unrelated.
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